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Summary
An HGPRT- cell line derived from mouse L cells 
has been shown to have the following properties: 
it is CRM+; the defective HGPRT molecules are 
altered in the carboxyterminal peptide; the mu­
tant cells regain HGPRT activity when ochre-sup­
pressor tRNA is microinjected into them, but not 
when am ber-suppressor or wild-type tRNAs are 
injected. We conclude from th ese  properties that 
this mutant cell line contains an ochre nonsense 
mutation (UAA) in the structural gene for HGPRT.
Introduction
The isolation and characterization of nonsense mu­
tants and nonsense suppressors in mammalian 
cells should provide a valuable new tool for genetic 
analysis of mammalian cells and their viruses. For 
example, the classification of a mutation as sup­
pressible by a nonsense suppressor provides a 
strong criterion that the mutation is in a structural 
gene. This inference can be made because of the 
very nature of nonsense mutants and their suppres­
sors. A nonsense mutation generates an in-phase, 
polypeptide-chain-termination codon (UAA, UAG 
or UGA) in the interior portion of a structural gene. 
As a consequence of this mutation, an aminoter- 
minal polypeptide fragment, rather than the com­
pleted polypeptide chain, is synthesized (Sarabhai 
et al., 1964). In bacteria and yeast, suppressors of 
nonsense mutations arise from mutations in tRNA 
genes which permit the mutant tRNA to translate a 
term ination codon as an amino acid codon (Capec­
chi and Gussin, 1965; Engelhardt et al., 1965; 
Goodman et al., 1968; Capecchi, Hughes and 
Wahl, 1975; Gesteland et al., 1976). Thus in the 
presence of a suppressor tRNA, the completed 
polypeptide product of a nonsense mutant can be 
synthesized. If the amino acid inserted at the site of 
the mutation does not markedly alter the protein 
structure, then an active gene product may be re­
stored.
Nonsense mutants are clearly conditional lethal 
mutations, since the physiological effect of the 
nonsense mutation can be studied in the presence 
and absence of the suppressor. It is of practical 
importance that this should be a very stringent 
conditional lethal system in mammalian cells. The 
expectation of stringency is based upon the fo llow ­
ing considerations: most NH2 terminal polypeptide 
fragments should not exhibit biological activity; 
such fragments are probably rapidly degraded in 
mammalian cells (Capecchi et al., 1974); and cell- 
free protein synthesis experiments indicate that the 
level of “ read-through” of a nonsense mutation in 
the nonpermissive system is less in mammalian 
cell-free extracts than in the comparable bacterial 
extracts (Capecchi et al., 1975).
The question of stringency of this potential con­
ditional-lethal system is an important one, since 
application of the other common conditional-lethal 
system (temperature-sensitive mutations) to mam­
malian cell studies has met with some technical 
d ifficulty. The versatility of temperature-sensitive 
mutants has been limited because mammalian cells 
cannot be grown over as wide a temperature range 
as bacteria or yeast. As a result of this narrow 
range, many temperature-sensitive mutants iso­
lated in mammalian cells and their viruses are 
“ leaky” —that is, they exhibit measurable activity at 
the nonpermissive temperature.
A further important property of the nonsense/ 
nonsense-suppressor system is that the affected 
mutant gene product can often be identified, since 
one can usually distinguish between the mutant 
polypeptide fragment and the suppressed com­
plete polypeptide chain.
The strategy which we adopted to search for 
nonsense mutants and their suppressors in mam­
malian cells was to start by isolating a large number 
of mouse L cell lines deficient for the nonessential 
enzyme hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT; E.C. 2.4.2.8). This enzyme 
catalyzes the conversion of the purines hypoxan- 
thine and guanine to their respective nucleotides 
IMP and GMP. It was selected as the target enzyme 
fo r these studies fo r a number of reasons. The 
enzyme can be readily assayed in cell-free extracts 
and in intact cells. Selective methods fo r isolating 
cell lines having lost or regained enzymatic activity 
had been developed (Szybalski, Szybalska and 
Ragni, 1962; Littlefield, 1963). Purine analogues, 
such as 8-azaguanine and 6-thioguanine, kill cells 
containing HGPRT and select fo r resistant cell lines 
which have reduced HGPRT activity. Such mutants 
remain viable because purine nucleotides can be 
synthesized by de novo pathways in the absence of 
HGPRT. Revertants, which have regained HGPRT 
activity, can be selected by blocking de novo pu­
rine biosynthesis with methotrexate and simultane­
ously supplying hypoxanthine. Such treatment ren­
ders the cells dependent upon HGPRT for synthesis 
of purine nucleotides from hypoxanthine.
Because it seemed probable that most nonsense 
mutants would exhibit very little enzymatic activity, 
the purine analogue concentration (8-azaguanine
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plus 6-thioguanine) use fo r isolating the HGPRT 
cell lines was chosen so that all the surviving clones 
contained <0.1% of the parental HGPRT activity.
These mutant cell lines were then divided into 
two classes: those which had lost enzymatic activ­
ity but still retained protein which cross-reacted 
with antisera prepared against purified HGPRT 
(CRM+), and those which had lost both enzymatic 
activity and immunological cross-reactivity 
(CRM- ). The cross-reacting material from the 
CRM+ mutants could be analyzed by standard 
methods of protein chemistry to determine whether 
the CRM exhibited smaller subunit molecular 
weights relative to the parental HGPRT molecules. 
If certain CRMs appeared to be fragments, one 
could further ask whether the alteration occurred 
at the carboxyterminal end of the polypeptide chain 
as predicted for nonsense mutants. The CRM- cell 
lines, which were expected to contain most of the 
HGPRT- nonsense mutants, were more d ifficu lt to 
analyze. Two separate approaches were used. 
First, the CRM- cell lines were tested fo r sensitivity 
to phenotypic suppression by m icroinjection of 
suppressor tRNA (to be described). Second, as­
suming that the collection of CRM- mutants con­
tained suppressible nonsense mutants, revertants 
from each of the CRM- mutant cell lines were iso­
lated and tested in vitro for suppressor tRNA activ­
ity.
Results 
Properties of the HGPRT Cell Lines
The HGPRT-  mutants used in this study were se­
lected, after mutagenesis w ith nitrosoguanidine, 
for resistance to the purine analogues 8-azagua- 
nine and 6-thioguanine (Sharp, Capecchi and Ca- 
pecchi, 1973). As previously mentioned, each of 
these cell lines contains <0.1% of the HGPRT activ­
ity present in the parental mouse L cells. A specific 
antibody directed against highly purified mouse- 
liver HGPRT was used fo r detect CRM in these 
HGPRT-  clones. Two methods for detecting CRM 
activity were used: a standard precipitation inh ib i­
tion assay (Suskind, 1957) and a radioimmune pre­
cipitation assay (Wahl, Hughes and Capecchi, 
1975). The latter assay proved to be much more 
sensitive for detection of altered HGPRT mole­
cules. By these methods, 40% of the HGPRT-  cell 
lines were shown to contain CRM. Since the 
amount of CRM varies among cell lines, the distinc­
tion of CRM+ from CRM- lines must be an opera­
tional one, based on some arbitrarily chosen lim it 
of detectable CRM. We designated a cell line as 
CRM+ if it contained >1% of the amount of CRM 
present in the parental cell line in an equivalent 
assay. Examination of the physical properties of
CRM from different mutant cell lines indicated that 
they arose from mutations at many different loci 
w ithin the HGPRT structural gene (Wahl et al., 
1975). The vast majority of these independently 
isolated CRMs did, however, have subunit molecu­
lar weights indistinguishable from wild-type 
HGPRT. In retrospect, this is not a very surprising 
result. We examined the rates of degradation of 
several missense mutants of HGPRT and found that 
they are selectively degraded 20-100 fold faster 
than the wild-type protein (Capecchi et al., 1974). 
These studies showed that even a small change in a 
protein, such as a missense mutation that leaves 
the protein still immunologically detectable, is suf­
ficient to cause rapid selective degradation. Most 
nonsense mutants seem likely to be degraded even 
faster. Following this line of reasoning, the only 
nonsense mutants we might have expected to es­
cape rapid degradation and be detected as CRM+ 
were those resulting from the introduction of a 
nonsense codon very near the carboxyterminal end 
of the coding region. In fact, as shown in Figure 1, 
the HGPRT-  CRM+ mutant which we discuss in this 
manuscript is not resolved from wild-type HGPRT 
by electrophoresis in SDS-urea polyacrylamide 
gels. Nevertheless, we demonstrate that this mu­
tant contains an altered carboxyterminal tryptic 
peptide, and that the chromatographic behavior 
and amino acid composition of this peptide are 
consistent with the fact that it is shorter than the 
corresponding wild-type peptide. For the experi­
ment shown in Figure 1, mutant and wild-type cells 
were labeled with 35S- and 3H-methionine, respec­
tively; extracts were prepared and immunoprecipi- 
tated with anti-HGPRT sera. The immune precipi­
tates were then mixed and electrophoresed on 
SDS-urea polyacrylamide gels. The resolving 
power of this gel is approximately ±700 daltons 
(that is ± six amino acids).
Tryptic Peptide Analysis of Wild-Type and Mutant 
HGPRT
The ability to resolve differences between mutant 
and wild-type HGPRT is greatly enhanced by exam­
ination of their tryptic peptides. Furthermore, an 
analysis of the tryptic peptides should afford the 
opportunity to identify the carboxyterminal pep­
tide. Since nonsense mutants generate NH2 term i­
nal polypeptide fragments, it is clearly important to 
look for changes in the carboxyterminal region of 
the protein.
The processing of the mutant and wild-type 
HGPRT for tryptic peptide analysis includes label­
ing the proteins in vivo w ith the desired radioactive 
amino acids, preparing extracts, immunoprecipi- 
tating the HGPRT molecules and purifying the im­
mune precipitates by SDS-urea polyacrylamide gel
Nonsense Mutants in Mammalian Cells
373
17 25 33 41 49 
F rac tion  No.
Figure 1. Analysis o f HGPRT Isolated From L+ and Mutant 
(HGPRT~, CRM+) Cell Extracts by Radioimmune Precipitation and 
SDS-Urea Polyacrylamide Gel Electrophoresis 
The L+ and mutant cell lines were labeled w ith3H- and 35S-methio- 
nine, respectively; the cell extracts were prepared and treated 
w ith antiserum against HGPRT and antibody against rabbit IgG. 
The radioimmune precipitates were then mixed and subjected to 
electrophoresis in an SDS-urea polyacrylamide gel. The gel was 
internally standardized with fluoresceinated myoglobin (MYO) 
and aldolase (ALD).
electrophoresis. The mutant and wild-type HGPRT 
are then eluted from their respective gels, mixed 
and trypsinized with enzyme that has been treated 
with the chymotrypsin inh ib itor TPCK. The tryptic 
peptides are separated by cation-exchange chro­
matography using a procedure sim ilar to that de­
veloped by Milman, Krauss and Olsen (1977) for 
analyzing the tryptic peptides of human HGPRT.
In Figure 2, we illustrate an experiment in which 
L+ cells were labeled with 35S-methionine. The pro­
file of the methionine-containing tryptic peptides of 
HGPRT is relatively simple. Peptides I and III con­
tain one methionyl residue, whereas peptide II ap­
pears to contain two. There is a fourth methionine- 
containing peptide (illustrated in Figures 5 and 6) 
which requires strong base to be eluted from the 
column. These results are consistent w ith the 
amino acid composition analysis of purified 
mouse-liver HGPRT, which indicated that the pro­
tein contains five methionyl residues per 27,000 
daltons of protein (unpublished results).
Fraction No.
Figure 2. Analysis of the Methionine-Containing Tryptic Peptides 
of HGPRT by Cation-Exchange Chromatography 
L+ cells were labeled with 35S-m ethionine. The labeled HGPRT 
was purified from the cell extract by immune precipitation and 
SDS-urea polyacrylamide gel electrophoresis. The HGPRT mole­
cules eluted from the gel were digested with TPCK-treated trypsin, 
and the peptides were separated by chromatography in ESiorad- 
aminex 5 resin using a pyridine acetate gradient.
In Figure 3, we compare the elution profile of the 
methionine-containing tryptic peptides of HGPRT 
isolated from the mutant, labeled with 3H-methio- 
nine, and wild-type cells, labeled with 35S-methio- 
nine. The mutant and wild-type HGPRT molecules 
were mixed prior to digestion w ith trypsin and then 
chromatographed on the cation-exchange column. 
Mutant peptide I elutes from the column before the 
corresponding wild-type peptide. We conclude 
from this that the mutant peptide is either shorter 
than, or more negatively charged than, the wild 
type peptide or both.
The tryptic peptide profile shown in Figure 4 is 
from an experiment sim ilar to that shown in Figure 
3, except that the radioactive labels were reversed. 
We observe again that the mutant peptide I elutes 
from the column ahead of the wild-type peptide.
If the mutant in question was a nonsense mutant, 
the prediction was that peptide I is the carboxyter- 
minal tryptic peptide of HGPRT. That this was so is 
shown in Figures 5 and 6. Figure 5 shows that the 
methionine-containing peptides II and IV are lysyl 
tryptic peptides. Figure 6 shows that peptide III 
contains arginine. Peptide I, however, contains 
neither lysine nor arginine. Since trypsin specifi­
cally cleaves pro te irs after lysine and arginine, and 
peptide I contains neither, peptide I must be the 
carboxylterminal tryptic peptide of HGPRT.
We mentioned earlier that the mutant carboxyter- 
minal peptide is either shorter than, or more nega­
tively charged than, the corresponding wild-type 
peptide or both. We favor the interpretation that the 
mutant peptide is shorter fo r the follow ing reasons. 
The pH of the column at the elution position of the 
altered peptide was sufficiently low that it could not
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be more negatively charged by having acquired an 
acidic amino acid residue. Furthermore, it could 
not be more negatively charged by having lost a 
basic residue since the wild-type peptide did not 
contain lysine or arginine. Similarly, it could not be 
more negatively charged by having lost a histidine 
residue since neither the wild-type nor the mutant 
peptides contained histidine (see Figure 7). By 
elim ination, therefore, we are left w ith the hypothe­
sis that the mutant peptide is shorter than the wild- 
type one. Direct testing of this hypothesis w ill have 
to await sequence analysis.
These results are consistent w ith the hypothesis 
that this CRM+ mutant is a nonsense mutant; how­
ever, a word of caution should be entered at this 
point. Showing that a mutant protein has a smaller 
subunit molecular weight than the wild-type pro­
tein and even showing that the alteration occurs at 
the carboxyterminal end of the protein is consistent 
w ith, but does not prove, that the mutation is a 
nonsense mutation. Alternative explanations in­
clude that the mutation is the result of a small 
internal deletion at the carboxyterminal end; that it 
is a frameshift mutation; or that it is an error in 
post-synthetic processing. Indeed, we believe that 
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Figure 3. Analysis o fth e  Methionine-Containing Tryptic Peptides 
o f HGPRT Isolated From L+ and Mutant (M) Cell Extracts 
L+ and mutant cells were labeled w ith 3SS - and 3H-methionine, 
respectively. The wild-type and mutant HGPRT was purified from 
cell extracts by immune precipitation and SDS-urea polyacryl­
amide gel electrophoresis. The purified proteins eluted from the 
gels were mixed, digested with TPCK-treated trypsin and analyzed 
as described in Figure 2.
is of interest since HGPRT does not appear to be a 
protein destined for export. Thus processing of 
mammalian proteins may be a much more general 
phenomenon than previously believed.
Processing of HGPRT?
As previously mentioned, the majority of HGPRT- 
CRM+ mutants have subunit molecular weights in­
distinguishable from wild-type protein. We have 
isolated mutants with altered subunit molecular 
weights however, and while some are smaller, oth­
ers are larger than wild-type HGPRT. Examples of 
such mutants are illustrated in Figure 8. The CRMs 
shown migrate respectively faster than, the same 
as and slower than wild-type HGPRT on calibrated 
SDS-urea polyacrylamide gels. The altered migra­
tion of the mutants could reflect altered levels of 
post-synthetic chemical modification of HGPRT 
(carbohydrate addition, phosphorylation, adenyla- 
tion and so on). To date, however, we have failed to 
generate any data which would support the idea 
that HGPRT is post-synthetically chemically modi­
fied. We therefore believe that the altered m obili­
ties of the CRMs in SDS-urea polyacrylamide gels 
reflect altered subunit molecular weights of the 
mutant proteins. We believe that most of these 
mutants are not nonsense mutants fo r a number of 
reasons. First, some are clearly larger than wild- 
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Figure 4. Further Analysis o f the Methionine-Containing Tryptic 
Peptides of HGPRT Isolated From L+ and Mutant (M) Cell Extracts 
The experiment shown in this figure was as described in Figure 5, 
except that the radioactive labels were reversed.







Figure 5. Analysis of the Lysine- and Methionine-Containing Tryptic Peptides of HGPRT
Mouse L+ cells were separately labeled w ith 35S-m ethionine and 3H-lysine. The labeled HGPRT was purified and trypsinized, and the 
peptides were analyzed as described in Figure 2. The methionine-containing peptides II and IV also contain lysine. A nonmethionine- 
containing lysyl peptide elutes just after peptide IV. The reasons for believing that peptide IV is a legitimate tryp tic peptide of HGPRT are that 
it is always found to be present in a ratio of one to  one relative to peptides I and III, and that the ratio o f m ethionine to lysine in peptide IV is 1 
and not <1. The radioactive material beyond peptide IV, which requires 1 N NaOH fo r elution, may represent more complex tryptic products 
(that is, unresolved peptides o r polypeptides which have not been completely hydrolyzed by trypsin).
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376
50  100 150
Fraction No.
Figure 6 . Analysis o f the Arginine- and Methionine-Containing Tryptic Peptides of HGPRT
The analysis is as described in Figure 5, except that mouse L+ cells were labeled with 3H-arginine instead o f 3H-lysine. A nonmethionine- 
containing arginyl tryp tic  peptide elutes just ahead of peptide IV. Peptide III is observed to contain arginine.
Fraction No.
Figure 7. Analysis of the Histidine- and Methionine-Containing Peptides of HGPRT
The analysis is as described in Figure 5, except that mouse L+ cells were labeled with aH -histid ine instead of 3H-lysine. It is noted that 
peptide I does not contain histidine.
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Figure 8 . Analysis of the Electrophoretic M obility of Three 
HGPRT", CRM+ Mutants in SDS-Urea Polyacrylamide Gels 
Mouse L+ cells were labeled with 3H-lysine and HGPRT-  CRM- 
mutant cells w ith 35S-m ethionine. The wild-type and mutant 
HGPRT molecules were purified and subjected to electrophoresis 
in SDS-urea polyacrylamide gels as described in Figure 1.
such mutants retain their altered subunit molecular 
weight. Third, they are not sensitive to phenotypic 
suppression. Rather, we believe that many of these 
mutants with altered subunit size represent struc­
tural gene mutants, which as a result of the muta­
tion have acquired alternate processing sites. 
Proof of this hypothesis w ill require primary struc­
tural analysis of the affected proteins.
One of the reasons fo r introducing the topic of 
processing of HGPRT is to point out the dangers of 
relying solely on altered subunit molecular weight 
as a criterion for a nonsense mutation and to em­
phasize the need to develop additional criteria. The 
approach which we have used to provide a second 
criterion is to introduce, by m icroinjection, sup­
pressor tRNA isolated from bacteria and yeast into 
the mutant cell line and to look for restoration of 
HGPRT activity (that is, a type of phenotypic sup­
pression).
Microinjection Experiments
Schlegel and Rechsteiner (1976), as well as Loy- 
ter, Zabai and Kulka (1975) have developed a
method for m icroinjection of macromolecules into 
mammalian cells in culture. The method involves 
fusing red blood cells preloaded with macromole­
cules to the mammalian cells using ultraviolet-inac­
tivated Sendai virus. The loading of the red blood 
cells with macromolecules is accomplished by hy­
potonic hemolysis of the red blood cells in the 
presence of the desired macromolecules. The de­
tails of loading and fusing of the red blood cells 
differ as described by the two groups. We have 
more closely followed the procedures of Schlegel 
and Rechsteiner (1975).
To be certain that m icroinjection was achieved 
under our experimental conditions, we injected 
HGPRT molecules into the mutant cell line. The 
macromolecules w ithin the red blood cells were 
removed by a prelysis step; the cells were then 
resealed, loaded with HGPRT and fused to the 
HGPRT-  cell line (Figure 9B). For comparison, red 
blood cells not loaded with HGPRT were also fused 
with the same cell line (Figure 9A). HGPRT activity 
present in the two populations of mouse L cells 
after fusion was determined by incubating the cells 
with 3H-hypoxanthine, fixing the cells, washing the 
fixed cells with 10% TCA to remove the unincorpo­
rated hypoxanthine and analyzing the level of in­
corporation by autoradiography. The cells which 
were fused with HGPRT-loaded red blood cells 
have approximately 10 fold greater density of ex­
posed silver grains overlying them. The grain den­
sity over the control cells (Figure 9A) is typical for 
this cell line under comparable incubation and ex­
posure conditions whether or not the cells have 
been fused with unloaded red blood cells.
Assuming a Poisson distribution, an analysis of 
the number of null cells (those with low grain den­
sity, suggesting that they had not successfully 
fused with any HGPRT-loaded red blood cells) indi­
cated that on the average, we were fusing one 
loaded red blood cell per fibroblast cell.
Table 1 gives a quantitative analysis of the 
HGPRT microinjection experiment. The HGPRT ac­
tivity loaded into the red blood cells is given in units 
of concentration (activity per unit vol) relative to the 
activity in wild-type mouse L cells. The amount of 
HGPRT activity transferred to the mutant cell line 
was proportional to the amount of HGPRT loaded 
into the red blood cells. The volume of a red blood 
cell was approximately 1% of the volume of a 
mouse fibroblast cell. Thus the amount of HGPRT 
activity transferred was consistent with the fusion, 
on the average, of one red blood cell per fibroblast 
cell.
When we were confident that we could microin- 
ject HGPRT into the mutant cell line, we tested the 
effect of m icroinjecting suppressor tRNAs into our 
mutant cell line. Figure 10 gives the results of mi­




Figure 9. Autoradiographic Analysis of the HGPRT Activity Present in HGPRT- Mouse L Cells After Fusion with Red Blood Cells Containing
(B) and Not Containing (A) HGPRT Molecules
Human red blood cells were hypotonically lysed in the presence of a 20 fold excess of buffer to remove internal macromolecules, resealed 
and loaded with purified HGPRT (B) and bovine serum albumin (A). The loaded red blood cells were fused to the HGPRT- cell line using 
ultraviolet-inactivated Sendai virus. After fusion, the cells were plated onto glass coverslips and incubated at 37°C for 36 hr. HGPRT activity 
was then measured by incubating the cells with 3H-hypoxanthine, fixing the cells with methanol, washing the cells with 10% TCA and 
overlaying the cells with autoradiographic emulsion. The autoradiograms were exposed in the dark for 72 hr and developed.
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Table 1. Microinjection of HGPRT into the HGPRT- Mouse L Cell 
Line
HGPRT Loaded into 
Red Blood Cells
3H-Hx Incorporated by 
HGPRT- Fibroblast 
After Fusion (CPM)





Human red blood cells were hypotonically lysed in the presence of 
a large excess of buffer to remove the internal macromolecules 
and resealed. The red blood cells were then loaded with three 
concentrations of purified HGPRT (0, 1X and 2X). The units of 
HGPRT are given as the concentration present in L+ cells. The 
HGPRT activity transferred to the mutant L cell line was deter­
mined by measuring in culture the incorporation of 3H-hypoxan- 
thine into TCA-precipitable product. The ratio of endogeneous 
human HGPRT activity to the loaded mouse HGPRT in the 1X and 















Figure 10. Restoration of HGPRT Activity to the HGPRT- Cell 
Line by Microinjection of E. coli Ochre-Suppressor tRNA 
Human red blood cells, loaded with increasing concentrations of 
tRNA, were fused to the mutant L cell line using ultraviolet- 
inactivated Sendai virus. The tRNA was isolated from three strains 
of E. coli: S26, S26R1E and PS2 which contain no suppressor, an 
amber-suppressor and an ochre-suppressor, respectively. The 
units of tRNA along the abscissa are given as the concentration of 
tRNA loaded into the red blood cells. HGPRT activity after fusion 
was measured in culture by determining the level of 3H-hypoxan- 
thine incorporation into a TCA-precipitable product.
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Figure 11. Restoration of HGPRT Activity to the HGPRT- Cell 
Line by Microinjection of Yeast Ochre-Suppressor tRNA 
The experimental details were as described in Figure 10, except 
that the sources of tRNA were three related strains of yeast: 
SL110-4D, D599-4B and D604-7D containing no nonsense sup­
pressor, an amber-suppressor and an ochre-suppressor, respec­
tively.
genic strains of E. coli into the mutant cell line. The 
strains were S26 (the suppressor-minus parental 
strain), S26RIE (which contains an Sul amber sup­
pressor) and PS2 (which contains the correspond­
ing ochre-suppressor). The tRNAs were purified 
using benzoylated-DEAE-cellulose chromatogra­
phy as previously described (Capecchi et al., 1975). 
HGPRT activity was measured 36 hr after fusion 
with the loaded red blood cells. M icroinjection of 
ochre-suppressor tRNA into the HGPRT^ cell line 
specifically restored HGPRT activity.
Figure 11 shows a sim ilar experiment, except 
that the sources of tRNAs were three closely related 
strains of yeast, S. cerevisiae. We observed again 
that only the yeast ochre-suppressor tRNA restores 
HGPRT activity to the mutant cell line.
Discussion
We have described an HGPRT-  mutant cell line 
derived from mouse L cells with the follow ing prop­
erties: first, it contains approximately 0.08% of the
5 10
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HGPRT activity present in the parental cell line; 
second, it is CRM+; th ird, it has an altered carboxy- 
terminal tryptic peptide whose chromatographic 
behavior is consistent with this peptide being 
shorter than the corresponding wild-type peptide; 
fourth, the mutant can be phenotypically corrected 
by m icroinjecting into the cells ochre-suppressor 
tRNA from either bacteria or yeast, but not by in­
jecting amber-suppressor or wild-type tRNA from 
the same sources. From these properties, we con­
clude that this mutant contains an ochre nonsense 
mutation in the HGPRT structural gene.
The obvious next step is to analyze a series of 
revertants of this mutant for suppressor tRNA activ­
ity. For this purpose we have developed in vitro 
suppressor assays using mammalian protein-syn­
thesizing components (Capecchi et al., 1975; un­
published results). The mutant does revert to 
HGPRT+ at a frequency of 10~7 after mutagenesis.
A number of investigators have reported 
shortened mutant gene products in higher eucary- 
otes and their viruses. Epstein, Waterson and Bren­
ner (1974) have reported a mutant nematode which 
contains a shortened myosin peptide. Adetugbo, 
Milstein and Secher (1977) have described a mu­
tant myeloma cell line which synthesizes a 
shortened immunoglobulin H chain, and Summers, 
Wagner and Summers (1975) have reported Herpes 
simplex viral mutants containing shortened thym i­
dine kinase peptides. Some of these mutants have 
subsequently been shown to have been generated 
by internal deletions orfram eshift mutations. Most 
recently, R. F. Gesteland and his co-workers have 
isolated nonsense mutants in an SV40-adeno virus 
hybrid (personal communication). These investiga­
tors can identify the cell-free translation product of 
the affected gene and suppress it in vitro by the 
addition of the appropriate suppressor tRNA.
Experimental Procedures
The methods used for culturing the cells, labeling the cells with 
radioactive precursors, preparing the cell extracts, immunopre- 
cipitating HGPRT, processing the immunoprecipitates and elec- 
trophoresing the immunoprecipitates on SDS-urea polyacryl­
amide gels have been described in detail elsewhere (Sharp et al., 
1973; Wahl et al., 1975; Capecchi et al., 1975).
Trypsin-Digestion of HGPRT
Wild-type L+ and mutant cells were grown to 75% confluency on 
100 mm plates containing MEM plus 10% fetal calf serum. The 
medium was removed and replaced with 3.0 ml of MEM contain­
ing 100 juCi/ml of the desired radioactively labeled amino acid 
(spec. act. approximately 20 mCi//imole). The cells were then 
incubated with gentle shaking for 24 hr at 30°C. The isotopically 
labeled HGPRT molecules were purified from cell extracts by 
immunoprecipitation and SDS-urea polyacrylamide gel electro­
phoresis. The gels were cut into 1 mm slices, and the HGPRT was 
eluted from the gel slices by gently shaking them in 0.6 ml of 
0.01% SDS for 36 hr at 30°C. The fractions containing the labeled 
HGPRT were determined by counting a 20 /ul aliquot of each 
supernatant in a Packard Tri-Carb scintillation counter. The ap­
propriate fractions (1-2 per gel) were pooled and lyophilized. SDS 
was removed by resuspending the samples in 150 /xl of water, 
precipitating the protein with 25% TCA and washing the precipi­
tates twice with 1 N HCl. The samples were then resuspended in 
100 ni of a 1% ammonium bicarbonate solution (pH 8.1), and 3 /xg 
of trypsin (Worthington-193 /i/mg) were added. After the samples 
had incubated for 2 hr at 30°C, 50 /xl of the bicarbonate solution 
and 2 /xg more trypsin were added. Trypsin digestion was contin­
ued for an additional 12 hr at 30°C. The ammonium bicarbonate 
was removed from the samples by lyophilization.
Analysis of th^ HGPRT Tryptic Peptides
The tryptic peptides of HGPRT were fractionated by cation-ex­
change chromatography at 50°C on an Aminex A-5 (Bio Rad) 
column. The lyophilized tryptic digests were resuspended in 100 
/xl of H20 , acidified by adding 5 /xl of formic acid and loaded onto 
a 2 mm x  150 mm column. The samples contained from 2000­
10,000 cpm. The flow rate was maintained at approximately 4 ml/ 
hr using a Milton Roy minipump at a pressure of approximately 
400 psi. After the sample was loaded, 2.0 ml of 0.1 M pyridine 
acetate (pH 3.5) were passed through the column. The peptides 
were eluted using a 28 ml linear pyridine acetate gradient [from 
0.1 M (pH 3.5) to 1.1 M (pH 5.2)]. At the end of the gradient, the 
column was washed with 2.0 ml of 2 M Tris (pH 8.0) and 8.0 ml of 1 
N NaOH. 0.2 ml fractions were collected. The radioactivity in each 
fraction was determined by adding 2.5 ml of scintillation fluid and 
counting the solution in a Packard Tri-Carb counter.
Microinjection of HGPRT into the Mutant Cell Line
10 ml of human blood were collected into a heparin-treated vacu- 
tainer to prevent coagulation. The serum and white blood cells 
were carefully removed during four washes with Hank’s solution. 
The red blood cells were preswollen by resuspending 0.5 ml of 
packed cells in 5.0 ml of 60% Hank’s. The swollen red blood cells 
were centrifuged at 650 x g for 12 min, and the supernatant was 
carefully removed. The endogenous level of HGPRT in the red 
blood cells was reduced by the following procedure: 0.5 ml of 
loading buffer [0.01 M Tris (pH 7.4), 0.005 M DTT] and 2.5 ml of 
25% Hank’s were added to 0.5 ml of preswollen red blood cells; 
the mixture was vortexed and incubated at 0°C for 2.5 min. After 
incubation, hemolysis was stopped by adding 400 /il of 10x 
Hank’s solution. The cells were then incubated for 1 hr at37°C and 
washed 3 times with Hank's. Analysis of the HGPRT content within 
the red blood cells before and after the hemolysis procedure 
indicated that the enzymatic activity per cell was reduced 7 fold.
Purified mouse HGPRT was then loaded into these red blood 
cells by mixing 0.5 ml of packed red blood cells with 0.5 ml of 
loading buffer containing the desired amount of HGPRT activity. 
The cells were again incubated for 2.5 min at 0°C, and hemolysis 
was stopped by adding 125 /il of 10x  Hank's. The loaded red 
blood cells were then incubated for 1 hr at 37°C. After incubation, 
the cells were washed twice with Hank's solution and once with a 
buffer of 0.02 M Tris (pH 7.4) and 0.150 M NaCl. Final resuspen­
sion of the HGPRT-loaded red blood cells was in 0.02 M Tris (pH 
7.4), 0.150 M NaCl and 0.002 M MnCI2. An aliquot of the loaded 
red blood cells was analyzed for HGPRT content. The amount of 
HGPRT loaded into the red blood cells was proportional to the 
amount of HGPRT present in the loading buffer during the hemol­
ysis step.
Fusion of the loaded red blood cells with the HGPRT- mouse 
fibroblast cells was accomplished by mixing 2 x  105 mouse cells 
(in 0.2 ml of 0.02 M Tris, 0.150 M NaCl and 0.002 M MnCI2) with 2 x  
107 loaded red blood cells (also in 0.2 ml) and 500 HA units of 
ultraviolet-inactivated Sendai virus (also in 0.2 ml). The mixture 
was incubated for 15 min at 0°C followed by a second incubation 
for 30 min at 37°C.
After fusion, the cells were resuspended in 5 ml of MEM plus 
10% FCS and plated onto 18 mm coverslips in a 60 mm petri dish. 
The cells were then incubated for 36 hr at 37°C in a 5% C02 
incubator and washed 3 times with warm MEM. The amount of 
HGPRT activity which was transferred during fusion to the
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HGPRT- mouse cells was determined by measuring the capacity 
of the cells to incorporate 3H-hypoxanthine into macromolecules. 
The cells were incubated for 6 hr at 37°C in MEM plus 10% FCS 
containing 15 ^iCi/ml of 3H-Hx (spec. act. 10 Ci/mmole). The cells 
were then washed 4 times with PBS, twice with methanol, once 
with 10% TCA and twice more with methanol. Autoradiography 
and direct scintillation counting were used to measure the level of 
3H-Hx incorporation. For direct scintillation counting, the cover- 
slips containing the fixed, washed cells were placed into scintilla­
tion vials, and 0.5 ml of 0.1% SDS solution were added. After 12 hr 
at room temperature, 10 ml of scintillation fluid were added, and 
the samples were counted in a Packard Tri-Carb counter. For 
autoradiographic analysis, the coverslips containing the fixed, 
washed cells were dipped in TNB-2 emulsion (Eastman-Kodak) 
diluted 1:1 with water. Following exposure for 72 hr, the slides 
were developed for 3 min with Kodak Dectol at 16°Cand fixed for 5 
min with Kodak Fixer.
As an internal measure of the number of mouse fibroblasts in 
each experiment, the fibroblasts were prelabeled with a low level 
of 32P04 (2.5 x  104 cpm/106 cells). The cells which were analyzed 
by autoradiography were not prelabeled with 32P0.,.
Microinjection of tRNA
The procedure for microinjecting tRNA into the mutant L cells was 
identical to the methods just described, except that tRNA was 
substituted in the loading buffer in place of HGPRT. The desired 
tRNAs were purified approximately 8 fold by chromatography on a 
benzoylated-DEAE column as previously described (Capecchi et 
al., 1975). After the red blood cells were loaded with amber- or 
ochre-suppressor tRNA, an aliquot of the cells was extracted with 
phenol to recover the tRNA, the aqueous phase was precipitated 
with 2 vol of ethanol and the precipitates were washed twice with 
70% ethanol. This tRNA was assayed for suppressor tRNA activity 
as previously described (Capecchi et al., 1975). Quantitative re­
covery of the suppressor tRNA activity was obtained, indicating 
that equilibrium of the tRNA across the red cell membrane was 
achieved during the loading procedure, and that tRNA activity was 
not destroyed within the red blood cells.
Wild-type as well as suppressor tRNA was microinjected into L+ 
cells at the concentrations indicated in Figures 10 and 11. Neither 
viability nor HGPRT activity was affected.
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